stockrow
Friday 6 November 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
93.82
0.28
+0.30%
Follow MIRM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 4 | 6 |
+8 more TTM periods Free account |
| (760.01%) | (702.97%) | (335.82%) | (8.65%) | ||
| (99.78%) | (97.15%) | (101.04%) | (3.09%) | ||
ROIC |
(184.65%) | (172.96%) | (298.98%) | (5.74%) | |
Return on Tangible Assets |
(294.61%) | (206.89%) | (267.15%) | (6.76%) | |
Average Days of Receivables |
85.08 | 85.84 | 85.30 | 86.35 | |
Free Cash Flow per Share |
(4.71) | (4.32) | (3.44) | 1.09 | |
Free Cash Flow |
(308.85) | (273.74) | (202.55) | 54.87 | |
Capital Expenditures |
(37.59) | (46.47) | (31.58) | (0.95) | |
| Other line items | |||||
Cash ROIC |
(29.39%) | (23.24%) | (21.57%) | 5.44% | |
Accounts Receivable Turnover |
5.09 | 4.90 | 4.98 | 5.17 | |
Accounts Payable Turnover |
9.50 | 5.50 | 2.99 | 8.27 | |
Inventory Turnover |
4.95 | 4.64 | 4.42 | 4.24 | |
Average Days of Payables |
40.63 | 75.70 | 204.48 | 35.01 | |
Days of Inventory on Hand |
75.88 | 83.27 | 87.85 | 90.62 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.09 | |
Research and Development Expense of Revenue |
164.54% | 165.88% | 169.30% | 35.71% | |
Selling, General and Administrative Expense of Revenue |
50.81% | 50.78% | 51.90% | 49.30% | |
Share Based Compensation of Revenue |
17.76% | 16.82% | 16.12% | 13.70% | |
Interest Coverage |
(78.36) | (62.06) | (55.27) | (1.54) | |
Operating CF/Net income |
0.30 | 0.26 | 0.21 | (2.39) | |
Depreciation/Fixed assets |
8.97 | 12.41 | 11.12 | 13.95 | |
Capex/Depreciation |
(1.29) | (1.66) | (1.18) | (0.04) | |
Revenue per Share |
10.24 | 9.75 | 9.68 | 10.39 | |
Operating CF per Share |
(4.14) | (3.59) | (2.91) | 1.11 | |
Capex per Share |
(0.57) | (0.73) | (0.54) | (0.02) | |
Capex to Sales |
0.06 | 0.08 | 0.06 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026